patients

LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…

1 day ago

Where to Get TMS Therapy in Colorado Springs Starts with Serenity Mental Health Centers

Serenity clinics offer accessible TMS treatment for mental health.COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Serenity Mental Health Centers, a leader in innovative psychiatric…

1 day ago

Serenity Mental Health Centers Expands Access in Colorado Springs with FDA-cleared Accelerated Deep TMS Protocol

Patients nationwide can access faster, convenient TMS treatment.COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Serenity Mental Health Centers, a leader in innovative psychiatric care…

2 days ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

October 31, 2025 16:30 ET  | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…

3 days ago

CeraVe Supports Global Skin Health Leaders to Deliver Care to Underserved Patients on World Skin Health Day

In Partnership with the International League of Dermatological Societies (ILDS) and the International Society of Dermatology (ISD), CeraVe Mobilizes 9…

5 days ago

Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the PARADIGM Trial)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company)…

7 days ago

Jupiter Endovascular Announces Positive Results From SPIRARE I First-in-human Study Presented at TCT 2025

Vertex Pulmonary Embolectomy System with Transforming Fixation (TFX) Technology Demonstrates Excellent Safety, Performance and Cardiac RecoveryMENLO PARK, Calif.--(BUSINESS WIRE)--#TFX--Jupiter Endovascular,…

1 week ago

ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors

SINGAPORE, Oct. 22, 2025 /PRNewswire/ -- ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, today announced encouraging early clinical findings…

1 week ago

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…

1 week ago

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing…

2 weeks ago